These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 21516403)

  • 1. Generation of lung cancer cell line variants by drug selection or cloning.
    Breen L; Keenan J; Clynes M
    Methods Mol Biol; 2011; 731():125-33. PubMed ID: 21516403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and culture of colon cancer cells and cell lines.
    Glaysher S; Cree IA
    Methods Mol Biol; 2011; 731():135-40. PubMed ID: 21516404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of retinoic acid on the growth of isogenic metastatic and non-metastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor beta isoforms 2 and 4.
    Hayashi K; Goodison S; Urquidi V; Tarin D; Lotan R; Tahara E
    Int J Oncol; 2003 Mar; 22(3):623-9. PubMed ID: 12579317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of in-vitro models of chemotherapy resistance.
    Watson MB; Lind MJ; Cawkwell L
    Anticancer Drugs; 2007 Aug; 18(7):749-54. PubMed ID: 17581296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
    Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
    Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
    Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
    Poste G
    Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor heterogeneity and the biology of cancer invasion and metastasis.
    Fidler IJ
    Cancer Res; 1978 Sep; 38(9):2651-60. PubMed ID: 354778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
    Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
    Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
    Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
    Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Isolation and characteristics of Chinese hamster cells resistant to colchicine].
    Efimova EV; Ignatova TN
    Tsitologiia; 1984 Mar; 26(3):316-22. PubMed ID: 6729994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines.
    Munker M; Munker R; Saxton RE; Koeffler HP
    Cancer Res; 1987 Aug; 47(15):4081-5. PubMed ID: 3038306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
    BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.